Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Litigation Details for Bayer Intellectual Property GMBH v. Warner Chilcott Company LLC (D. Del. 2012)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Bayer Intellectual Property GMBH v. Warner Chilcott Company LLC (D. Del. 2012)

Docket   Start Trial Date Filed 2012-08-13
Court District Court, D. Delaware Date Terminated 2015-05-13
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Plaintiff Referred To
Parties BAYER INTELLECTUAL PROPERTY GMBH; BAYER PHARMA AG; WARNER CHILCOTT (US) LLC; WARNER CHILCOTT COMPANY LLC; WARNER CHILCOTT PLC
Patents 4,921,843; 5,552,394; 7,704,984
Attorneys Richard D. Kirk; Stephen B. Brauerman; Tiffany Geyer Lydon; Vanessa Ribeiro Tiradentes
Link to Docket External link to docket
Small Molecule Drugs cited in Bayer Intellectual Property GMBH v. Warner Chilcott Company LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Bayer Intellectual Property GMBH v. Warner Chilcott Company LLC (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-08-13 1 .S. Patent No. 7,704,984 (the “’984 Patent”) in the Orange Book for Lo Loestrin. The ’984 Patent claims… ’940 Patent. The claims of the ’984 patent are not separately patentable over the ’940 Patent. …of U.S. Patent Number 5,980,940 (the “’940 Patent”). A true and correct copy of the ‘940 Patent is attached…regimen of the ’490 Patent. 21. The ’940 Patent is prior art to the ’984 Patent 22. … 1. This is an action for patent infringement arising under the patent laws of the United States, External link to document
2013-04-04 11 . 5,552,394.) Warner Chilcott’s brief fails to even address the possibility that the New Jersey litigation… ’940 patent interferes with Warner Chilcott’s patent—U.S. Patent No. 7,704,984 (“’984 patent”). (D.… Patent No. 5,756,490 (“’490 patent” or the “24-4 patent”). The 24-4 patent claims a regimen with 24 … THE PATENTS IN SUIT Bayer has asserted U.S. Patent No. 5,980,940 (“’940 patent”) against…enjoyment of patent rights in situations where the Patent Office has erroneously permitted two patents to issue External link to document
2015-04-21 139 Warner Chilcott's patent-U.S. Patent No. 7,704,984 ("the '984 Patent"}-interferes with…alleges infringement of U.S. Patent No. 5,980,940 ("the '940 Patent"). 1 Presently before…AG (collectively, "Bayer") filed this patent infringement lawsuit against defendants Warner …summary judgment on the grounds that the '940 Patent is indefinite and therefore invalid. (D.I. 131.…judgment. II. BACKGROUND The '940 Patent claims an oral contraception regimen in which two External link to document
2013-12-06 26 Warner Chilcott's U.S. Patent No. 7,704,984 ("'984 patent). (D.I. 5.) Warner Chilcott then …alleging infringement of U.S. Patent No. 5,980,940 ('"940 patent"). (D.I. 1.) Four months…claim for patent "interference" under 35 U.S.C. § 291 between the '940 patent and Warner… product infringes the '940 patent, and that the '984 patent purportedly covering Lo Loestrin…litigation"), asserting the '984 patent and another patent against the generics. (Id.) In response External link to document
2014-04-18 58 Exhibit A 4,921,843);Ehrlich patent (U.S. 5,280,023). effective estrogen … 4,921,843);Ehrlich patent (U.S. 5,280,023). high contraceptive …. U.S. Patent No. 4,921,843(“Pasquale”):1: … 4,921,843);Ehrlich patent (U.S. 5,280,023). low incidence of follicular…claim 1). U.S. Patent No. 4,921,843(“Pasquale”):1: External link to document
2014-05-09 62 between the ’940 patent and Warner Chilcott’s U.S. Patent No. 7,704,984 (“the ’984 patent”). The parties…Warner Chilcott”), infringes U.S. Patent No. 5,980,940 (“the ’940 patent”). Bayer further alleges statutory… ’940 patent. See D.I. 58 (Joint Claim Chart). I. INTRODUCTION The ’940 patent claims…’940 patent does not claim the first oral contraceptive. Accordingly, to obtain the ’940 patent, Bayer…terms. Id. B. The ’940 Patent The ’940 patent contains ten claims. Claim 1 is the External link to document
2014-06-13 67 set out in the prior art. [Ex. 6, U.S. Pat. No. 4,921,843 at 6:20-7:45 (“Pasquale”); Ex. 7, U.S. Pat. No…regimen in the patent’s specification. Both steps invite error. A. Bayer Patented A Novel Regimen…, as discussed in the ’940 patent’s specification. Second, the ’940 patent claimed a regimen with both…prior art patents also related to laryngeal mask devices which use the term.”). The Ehrlich patent states…the ’940 patented regimen with the Pearl Index of the Ehrlich regimen because neither patent discusses External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Harvard Business School
Merck
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.